SLS-009 (Sellas Life Sciences Group)

Phase 2a trial demonstrates promising 67% overall response rate for tambiciclib plus zanubrutinib combination in relapsed/refractory DLBCL patients, including one complete response.

SELLAS Life Sciences anticipates a pivotal 2025 with key clinical milestones for its hematologic malignancy therapies, including data readouts and regulatory feedback.

SELLAS Life Sciences reports that SLS009, a CDK9 inhibitor, shows promising results in a Phase 2 trial for relapsed/refractory AML.

SELLAS Life Sciences reports that SLS009, a CDK9 inhibitor, demonstrates high efficacy in preclinical models of solid cancers with ASXL1 mutations.

The T-cell malignancies market is experiencing growth driven by increased incidence, treatment advancements, and strategic biopharma partnerships.